JP2008156320A - Antioxidative functional water - Google Patents

Antioxidative functional water Download PDF

Info

Publication number
JP2008156320A
JP2008156320A JP2006350037A JP2006350037A JP2008156320A JP 2008156320 A JP2008156320 A JP 2008156320A JP 2006350037 A JP2006350037 A JP 2006350037A JP 2006350037 A JP2006350037 A JP 2006350037A JP 2008156320 A JP2008156320 A JP 2008156320A
Authority
JP
Japan
Prior art keywords
functional water
water
hydrogen
air
hydrogen peroxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006350037A
Other languages
Japanese (ja)
Inventor
Takashi Hattori
隆史 服部
Hisanori Tani
久典 谷
Hifumi Oishi
一二三 大石
Haruo Sato
春夫 佐藤
Shigetaka Horiuchi
茂隆 堀内
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FCC HORIUCHI KK
HYDROX KK
ONGA ENG KK
Onga Engineering Co Ltd
Original Assignee
FCC HORIUCHI KK
HYDROX KK
ONGA ENG KK
Onga Engineering Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FCC HORIUCHI KK, HYDROX KK, ONGA ENG KK, Onga Engineering Co Ltd filed Critical FCC HORIUCHI KK
Priority to JP2006350037A priority Critical patent/JP2008156320A/en
Publication of JP2008156320A publication Critical patent/JP2008156320A/en
Pending legal-status Critical Current

Links

Landscapes

  • Non-Alcoholic Beverages (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide a new function of water containing highly concentrated nano-sized bubbles. <P>SOLUTION: Functional water containing fine bubbles generated by aerating at least one gas selected from a group consisting of air, hydrogen, oxygen and nitrogen and having hydrogen peroxide-removing action, is provided. Such functional water can be simply produced by aerating at least one gas selected from a group consisting of air, hydrogen, oxygen and nitrogen through a microfiltration membrane, an ultrafiltration membrane or a gas separation membrane. The functional water is useful for treating metabolic syndrome, adiponectin-related diseases or conditions, or hypertension treatment and the like. <P>COPYRIGHT: (C)2008,JPO&INPIT

Description

本発明は空気、水素又は窒素ガスをマイクロバブル又はナノバブル状態で含む、機能水に関する。本発明の機能水は抗酸化作用を有する。本発明の機能水はまた、抗メタボリックシンドロームホルモンとされているアディポネクチンの産生を促進し、血圧を下げる効果がある。本発明の機能水は、食品、化粧品及び医薬品の分野で有用である。   The present invention relates to functional water containing air, hydrogen or nitrogen gas in a microbubble or nanobubble state. The functional water of the present invention has an antioxidant action. The functional water of the present invention also has the effect of promoting the production of adiponectin, which is considered as an anti-metabolic syndrome hormone, and lowering blood pressure. The functional water of the present invention is useful in the fields of food, cosmetics and pharmaceuticals.

近年、種々の機能や効能を唱えた機能水が提唱され始め、研究も若干行われ始めている。機能水とは、ある特定の物理的、化学的処理をした水、ある特定の物質を添加した水、ある特定の物質を除去した水、と定義が提案されている(非特許文献1)。   In recent years, functional water with various functions and effects has been proposed, and some research has begun. The definition of functional water has been proposed as water having a specific physical and chemical treatment, water having a specific substance added, and water having a specific substance removed (Non-patent Document 1).

現在、種々の生理学的機能を持つとされている機能水は主に電気化学的に分解した、いわゆる酸性水やアルカリ水である。前者については殺菌作用を有するとの報告があり(非特許文献2)、後者については消化器系愁訴の改善作用(非特許文献3)や活性酸素種の消去作用を有するとの報告がある一方で(非特許文献4)、活性酸素種の消去能はないとの報告もある(非特許文献5)。   At present, functional water which is considered to have various physiological functions is mainly so-called acidic water or alkaline water which is electrochemically decomposed. While the former has been reported to have a bactericidal action (Non-patent Document 2), the latter has a report of improving gastrointestinal complaints (Non-patent Document 3) and eliminating reactive oxygen species. (Non-Patent Document 4), there is a report that there is no scavenging ability of active oxygen species (Non-Patent Document 5).

最近では、マイクロバブル(MB)、マイクロナノバブル(MNB)、ナノバブル(NB)といった微細な気泡を含む水に関する研究が進みつつある。マイクロメーター以下の気泡を含む水は、水質の浄化、殺菌、水系生物の酸欠状態の改善等、従来の水にはない機能を有することが分かってきており、主として水産・養殖業において注目されている。例えば、海水マイクロバブルをホタテに供給した場合に、急激な血流促進が実現されたとの報告がある(非特許文献6)。また、水槽内に酸素ナノバブルを入れると、海水魚と淡水魚とを同時に半年以上の期間に渡って生存させることができたとの報告がある(特許文献1)。また、微細な気泡を発生させる手段としては、船舶等の走行中の水との摩擦を低減するために船体の表面に気泡又は空気層を介在させる目的で、空気ポンプで発生させた加圧空気を複数の穴や多孔板から水中に噴出させる方法(例えば、特許文献2及び3)、及び回転する気液2相流体の中心空洞部に気体を通過させ、出口付近で一挙に圧力解放させることでその空洞の回転切断部分でマイクロバブルを発生させる方法(前掲非特許文献6)等が提案されている。
特開2005-246294号 特開昭61-71290号 特開平8-230762号 ウォーターサイエンス研究会編、機能水実用ハンドブック、人間と歴史社、pp13〜14、2006 T. Kitahora et al: Active oxygen species in gastric mucosal lesion with Helicobacter pylori. Current Topics in Mucosal Immunology, 289-293, 1993 田代博一、他:Helicobacter pylori と胃粘膜組織発生活性酸素、消化器と免疫、71-73、1996 S. Shirahata et al: Electrolyzed-reduced water scavenges active oxygen species and protects DNA from oxidative damage. Biochem. Biophys. Res. Commun., 234, 269-274, 1997 内藤 祐二、他:非ステロイド系抗炎症薬による胃粘膜障害に対するアルカリイオン水の有効性の検討、第5回機能水シンポジウム抄録集、67-68、1998 大成 博文他、マイクロ・ナノバブルの発生機構と生理活性、日本混相流学会年会後援会講演論文集、221-222、2003 Ishida, N. et al., Langmuir, 16, 5681-5687, 2000
Recently, research on water containing fine bubbles such as microbubbles (MB), micronanobubbles (MNB), and nanobubbles (NB) has been progressing. Water containing bubbles below the micrometer has been found to have functions not found in conventional water, such as water purification, sterilization, and improvement of oxygen deficiency in aquatic organisms. ing. For example, there is a report that rapid blood flow promotion is realized when seawater microbubbles are supplied to scallops (Non-Patent Document 6). Moreover, when oxygen nanobubbles are put in the aquarium, there is a report that saltwater fish and freshwater fish can be simultaneously survived for a period of more than half a year (Patent Document 1). Further, as a means for generating fine bubbles, pressurized air generated by an air pump for the purpose of interposing bubbles or an air layer on the surface of the hull in order to reduce friction with water running on a ship or the like. A method of jetting water into a water from a plurality of holes or a perforated plate (for example, Patent Documents 2 and 3), and letting gas pass through the central cavity of a rotating gas-liquid two-phase fluid and releasing pressure at a stroke near the outlet A method for generating microbubbles at the rotationally cut portion of the cavity (Non-Patent Document 6) has been proposed.
JP 2005-246294 JP 61-71290 JP-A-8-230762 Water Science Study Group, Functional Water Practical Handbook, Human and History Company, pp13-14, 2006 T. Kitahora et al: Active oxygen species in gastric mucosal lesion with Helicobacter pylori.Current Topics in Mucosal Immunology, 289-293, 1993 Tashiro Hirokazu, et al .: Helicobacter pylori and gastric mucosal tissue-generated reactive oxygen, digestive organs and immunity, 71-73, 1996 S. Shirahata et al: Electrolyzed-reduced water scavenges active oxygen species and protects DNA from oxidative damage. Biochem. Biophys. Res. Commun., 234, 269-274, 1997 Yuji Naito, et al .: Examination of effectiveness of alkaline ionized water for gastric mucosal damage caused by non-steroidal anti-inflammatory drugs, 5th Functional Water Symposium, 67-68, 1998 Hirofumi Taisei, et al., Micro-Nano Bubble Generation Mechanism and Physiological Activity, Proceedings of Annual Meeting of Japan Multiphase Flow Society, 221-222, 2003 Ishida, N. et al., Langmuir, 16, 5681-5687, 2000

発明者らは長年メタボリックシンドロームの予防や治療方法の研究に従事してきた。そして、空気、水素等の非常に安全性の高い気体をナノサイズの気泡状態で高濃度に包含させた水が種々の機能を有することを見出した。また、このようなナノバブル水の品質が長期に渡り安定であることを確認し、本発明を完成した。   The inventors have been engaged in research on prevention and treatment methods of metabolic syndrome for many years. And it discovered that the water which included highly safe gas, such as air and hydrogen, in a high density | concentration in the state of a nanosize bubble had various functions. Moreover, it was confirmed that the quality of such nanobubble water was stable for a long time, and the present invention was completed.

本発明はすなわち:
1)空気、水素、酸素及び窒素からなる群より選択される気体の一種以上を曝気することにより生じた微細な気泡を含み、過酸化水素除去能を有する機能水;
2)空気、水素、酸素及び窒素からなる群より選択される気体の一種以上を、精密濾過膜、限外濾過膜、又はガス分離膜を介して曝気することにより生じた微細な気泡を含む機能水;
3)過酸化水素除去能を有する、上記2)の機能水;
4)メタボリックシンドローム、アディポネクチン、レプチン、TNF−α又は酸化障害に関連した疾患若しくは状態、又は高血圧の処置のための、上記1)〜3)のいずれかに記載の機能水;
5)空気、水素、酸素及び窒素からなる群から選択される気体の一種以上を曝気することにより生じた微細な気泡を含み、過酸化水素除去能を有する、抗酸化性機能水;
6)上記5)に記載の機能水を含む、食品組成物、化粧用組成物又は医薬組成物;
7)上記5)に記載の機能水を含む、メタボリックシンドローム、アディポネクチン、レプチン、TNF−α又は酸化障害に関連した疾患若しくは状態、又は高血圧の処置のための医薬組成物;
8)空気が理論溶存値の50倍含まれる、上記1)〜3)のいずれか1項に記載の機能水;
9)水素が理論溶存値の10倍以上含まれる、上記1)〜3)のいずれか1項に記載の機能水;
を提供する。
The present invention means:
1) Functional water containing fine bubbles generated by aeration of one or more gases selected from the group consisting of air, hydrogen, oxygen and nitrogen, and having hydrogen peroxide removal ability;
2) A function including fine bubbles generated by aeration of one or more gases selected from the group consisting of air, hydrogen, oxygen and nitrogen through a microfiltration membrane, an ultrafiltration membrane, or a gas separation membrane. water;
3) Functional water according to 2) above having hydrogen peroxide removing ability;
4) Functional water according to any one of 1) to 3) above for the treatment of metabolic syndrome, adiponectin, leptin, TNF-α or diseases or conditions associated with oxidative disorders, or hypertension;
5) Antioxidant functional water containing fine bubbles generated by aeration of one or more gases selected from the group consisting of air, hydrogen, oxygen and nitrogen, and having hydrogen peroxide removal ability;
6) A food composition, cosmetic composition or pharmaceutical composition comprising the functional water described in 5) above;
7) A pharmaceutical composition for the treatment of metabolic syndrome, adiponectin, leptin, TNF-α or oxidative disorder-related diseases or conditions, or hypertension, comprising the functional water described in 5) above;
8) Functional water according to any one of 1) to 3) above, wherein air is contained 50 times the theoretical dissolved value;
9) The functional water according to any one of 1) to 3) above, wherein hydrogen is contained 10 times or more of a theoretical dissolved value;
I will provide a.

一定以下の大きさの微細な気泡を含む水はマイナスの電位を有し、水面上に上昇することなく、圧壊現象により水中で消滅する。その際、瞬間的に超高温・超高圧状態になることから、水を構成している水素分子が物理的に解離し、原子状水素になると考えらる。原子状水素には還元作用があり、活性酸素の除去能がある。一方、水素分子は非常に安定であるため、室温下では化学的に不活性であり、高濃度に水素を水に溶解しても活性酸素の消去能は認められない(ウォーターサイエンス研究会 編、機能水実用ハンドブック、pp213〜225、2006年、人間と歴史社)。本発明は、微細な気泡を含む水の、上述のような還元作用を利用するものである。したがって、本発明に用いられる気体は、このような現象を生じうるものであり、かつ生体に対して安全性の高いものでありさえすれば、特に制限はない。本発明には、例えば空気、水素、酸素及び窒素からなる群より選択される一種以上の気体を用いることができる。好ましくは、空気、水素又は窒素を用い、より好ましくは空気又は水素を用いる。   Water containing fine bubbles of a certain size or less has a negative potential, and disappears in the water by a crushing phenomenon without rising on the water surface. At that time, since it is in an ultra-high temperature / ultra-high pressure state instantaneously, it is considered that hydrogen molecules constituting water physically dissociate into atomic hydrogen. Atomic hydrogen has a reducing action and is capable of removing active oxygen. On the other hand, since hydrogen molecules are very stable, they are chemically inert at room temperature, and even if hydrogen is dissolved in water at a high concentration, the ability to scavenge active oxygen is not recognized (edited by Water Science Research Group, Functional Water Practical Handbook, pp213-225, 2006, Human and History Company). The present invention utilizes the above-described reducing action of water containing fine bubbles. Therefore, the gas used in the present invention is not particularly limited as long as it can cause such a phenomenon and is highly safe for a living body. In the present invention, for example, one or more gases selected from the group consisting of air, hydrogen, oxygen, and nitrogen can be used. Preferably, air, hydrogen or nitrogen is used, and more preferably air or hydrogen is used.

本発明に用いることのできる水は、食品、化粧品又は医薬の製造に適していれば特に制限はない。本発明には、例えば硬水、軟水、中硬水、イオン交換水、脱塩水、水道水、滅菌水等を用いることができる。   The water that can be used in the present invention is not particularly limited as long as it is suitable for the production of foods, cosmetics or medicines. In the present invention, for example, hard water, soft water, medium hard water, ion exchange water, desalted water, tap water, sterilized water, and the like can be used.

本発明の機能水は、上述したような気体の一種以上を曝気することにより生じた微細な気泡を含む。このような機能水の製造方法としては従来技術を利用してもよい。   The functional water of the present invention contains fine bubbles generated by aeration of one or more kinds of gases as described above. A conventional technique may be used as such a method for producing functional water.

簡便には、精密濾過膜、限外濾過膜、ナノ濾過膜又はガス分離膜のようなマイクロメーター以下の微細な孔を有する有機系素材又は無機系素材の多孔質体を介して、加圧した気体を水中に送り込むことにより製造することができる。用いる膜の素材には、特に制限はなく、飲料の製造に適しており、かつ用いる加圧気体及び水に対して安定であればよい。曝気時間は、当業者であれば機能水が有すべき過酸化水素除去能等を指標に、曝気量、多孔質体表面積、水量に応じ、適宜設定することができる。例えば、有機系膜モジュールを用いた実施例に記載した条件では、約18時間、無機系フィルターモジュールを用いた実施例に記載した条件では、約2時間曝気を行うことが推奨される。曝気を行う際の温度は、好ましくは室温(25℃)であり、より好ましくは4℃〜10℃である。曝気を行う際のpHは、用いる多孔質体が安定である範囲内であればよい。例えば、実施例に記載したモジュールに関しては、pH1〜14の範囲内で実施することができる。   For convenience, pressure is applied through a porous body of an organic material or an inorganic material having fine pores of micrometer or less such as a microfiltration membrane, an ultrafiltration membrane, a nanofiltration membrane or a gas separation membrane. It can be manufactured by sending gas into water. There is no restriction | limiting in particular in the raw material of the film | membrane to be used, It is suitable for manufacture of a drink, and should just be stable with respect to the pressurized gas and water to be used. A person skilled in the art can appropriately set the aeration time according to the amount of aeration, the surface area of the porous body and the amount of water, using as an index the ability to remove hydrogen peroxide that the functional water should have. For example, it is recommended to perform aeration for about 18 hours under the conditions described in the embodiment using the organic membrane module and for about 2 hours under the conditions described in the embodiment using the inorganic filter module. The temperature at the time of aeration is preferably room temperature (25 ° C.), more preferably 4 ° C. to 10 ° C. The pH at the time of aeration should just be in the range with which the porous body to be used is stable. For example, the modules described in the examples can be carried out within the range of pH 1-14.

得られた機能水は、過酸化水素除去能、重量、気泡粒径等を測定することにより、評価することができ、またその機能の確認をすることができる。   The obtained functional water can be evaluated by measuring its ability to remove hydrogen peroxide, weight, bubble particle size, etc., and its function can be confirmed.

本発明の機能水は、過酸化水素除去能を有する。本明細書で機能水について「過酸化水素除去能を有する」というときは、特別な場合を除き、対象となる機能水に過酸化水素濃度が10ppmになるように過酸化水素水を添加し、密閉し、室温下に3時間静置した後、残存過酸化水素量を測定したときに、過酸化水素が少なくとも30%除去される(過酸化水素濃度が7ppm以下となる)ことをいう。本発明の機能水は、このような測定により評価される過酸化水素除去能において、40%以上であることが好ましく、50%以上であることがさらに好ましく、60%以上であることが一層好ましい。本発明の機能水の過酸化除去能の上限値は、製造上、安全上、保存安定上等の観点から定めることができ、例えば、99%、95%、90%又は85%とすることができる。   The functional water of the present invention has the ability to remove hydrogen peroxide. In the present specification, when it has “hydrogen peroxide removal ability” for functional water, except for special cases, hydrogen peroxide solution is added to the target functional water so that the hydrogen peroxide concentration becomes 10 ppm, After sealing and standing at room temperature for 3 hours, when the amount of residual hydrogen peroxide is measured, hydrogen peroxide is removed at least 30% (hydrogen peroxide concentration is 7 ppm or less). The functional water of the present invention is preferably 40% or more, more preferably 50% or more, and still more preferably 60% or more in terms of hydrogen peroxide removal ability evaluated by such measurement. . The upper limit value of the functional water peroxidation-removing ability of the present invention can be determined from the viewpoints of production, safety, storage stability, etc. it can.

なお、本明細書の実施例に記載した、空気を曝記することにより製造した機能水の場合、精密電子上皿天秤にて処理前後の重量を測定したところ、1mlの重量は、曝気前は0.9854g、曝気後は0.9633gであり、0.0022g軽くなっていた。また、同様に、水素を曝気することにより製造した機能水の場合は、曝気前は0.9854g、曝気語は0.9917gであり、0.0078g軽くなっていた。このような結果は、空気及び水素が水中に閉じ込められたために生じたものと考えられる。   In the case of functional water produced by exposing air, as described in the examples of this specification, the weight before and after treatment was measured with a precision electronic pan balance. 0.9854g, 0.9633g after aeration, 0.0022g was lighter. Similarly, in the case of functional water produced by aeration of hydrogen, 0.9854 g before aeration and 0.917 g of aeration word were 0.0078 g lighter. Such a result is thought to have occurred because air and hydrogen were trapped in water.

空気を曝気することにより製造された本発明の機能水に含まれる空気の量は、空気の水への理論溶存値の10倍以上であることが好ましく、50〜3,000倍であることがより好ましく、100〜1,000倍であることがさらに好ましい。水素を曝気することにより製造された本発明の機能水に含まれる水素の量は、水素の水への理論溶存値の3倍以上であることが好ましく、10〜200倍であることがより好ましく、20〜50倍であることがさらに好ましい。   The amount of air contained in the functional water of the present invention produced by aeration of air is preferably 10 times or more the theoretical dissolved value of air in water, more preferably 50 to 3,000 times. More preferably, it is 100 to 1,000 times. The amount of hydrogen contained in the functional water of the present invention produced by aeration of hydrogen is preferably at least 3 times the theoretical dissolved value of hydrogen in water, more preferably 10 to 200 times. 20 to 50 times more preferable.

本発明の機能水は、抗酸化作用を有する、抗酸化性機能水である。   The functional water of the present invention is an antioxidant functional water having an antioxidant action.

本発明の機能水は、食品組成物、化粧用組成物又は医薬組成物として、またはこれらのいずれかに添加して用いることができる。食品組成物には、飲料、ドリンク剤が含まれる。   The functional water of the present invention can be used as a food composition, cosmetic composition or pharmaceutical composition, or added to any of these. The food composition includes beverages and drinks.

本発明の機能水は、過酸化水素除去能又は抗酸化作用が有効な効果をもたらす、種々の用途に用いることができる。本発明の機能水は、特にメタボリックシンドローム、アディポネクチンに関連した疾患若しくは状態(例えば、肥満、内臓脂肪過多、生活習慣病、動脈硬化)、レプチンに関連した疾患若しくは状態(例えば、肥満、食欲過多、糖脂質代謝低下)、TNF−α(例えば、インスリン抵抗性、腫瘍)又は酸化障害(例えば、過酸化脂質の増加、動脈硬化、心筋梗塞、糖尿病、癌、老化)に関連した疾患若しくは状態、又は高血圧の処置のために有用である。   The functional water of the present invention can be used for various applications in which the ability to remove hydrogen peroxide or the antioxidant action has an effective effect. The functional water of the present invention may be used in particular for metabolic syndrome, adiponectin-related diseases or conditions (for example, obesity, visceral fat, lifestyle-related diseases, arteriosclerosis), leptin-related diseases or conditions (for example, obesity, anorexia, Diseases or conditions associated with reduced glycolipid metabolism), TNF-α (eg, insulin resistance, tumor) or oxidative disorders (eg, increased lipid peroxide, arteriosclerosis, myocardial infarction, diabetes, cancer, aging), or Useful for the treatment of hypertension.

本明細書において疾患又は状態について「処置」というときは、特別な場合を除き、その疾患又は状態について、治療すること、予防すること、進行を遅延又は停止すること、良好な状態を維持することが含まれ、治療には、症状を抑える対処的治療と、根本的な治療とが含まれる。   As used herein, “treatment” for a disease or condition, except for special cases, treats, prevents, delays or stops progression, or maintains a good condition for the disease or condition. The treatment includes coping treatment that suppresses symptoms and fundamental treatment.

アディポネクチンとは、脂肪細胞から血液中に分泌されるホルモンであり、メタボリックシンドローム解消のために効果があるといわれている。   Adiponectin is a hormone secreted into the blood from fat cells, and is said to be effective for eliminating metabolic syndrome.

本明細書で「メタボリックシンドローム」というときは、通常の意味で用いており、一般的な診断基準にしたがって、ウエスト周囲径が男性で85cm、女性で90cm以上(内臓脂肪面積100cm2以上のマーカー)を「要注意」とし、その中で(1)血清脂質異常(トリグリセリド値150mg/dL以上、又はHDLコレステロール値40mg/dL未満)、(2)血圧高値(最高血圧130mmHg以上、又は最低血圧85mmHg以上)、(3)高血糖(空腹時血糖値110mg/dL)の3項目のうち2つ以上を有する場合を指す。 In this specification, “metabolic syndrome” is used in the normal sense, and the waist circumference is 85 cm for men and 90 cm for women (marker with visceral fat area of 100 cm 2 or more) according to general diagnostic criteria. In this, "1) Serum lipid abnormality (triglyceride level 150 mg / dL or higher, or HDL cholesterol level less than 40 mg / dL), (2) High blood pressure (highest blood pressure 130 mmHg or higher, or lowest blood pressure 85 mmHg or higher" ), (3) refers to the case of having two or more of three items of hyperglycemia (fasting blood glucose level 110 mg / dL).

本発明の機能水は、肥満症、高血圧症、糖尿病及び高脂血症等の処置、並びに運動能の向上及び運動維持にも有用である。   The functional water of the present invention is also useful for treatment of obesity, hypertension, diabetes, hyperlipidemia, etc., as well as improvement of exercise capacity and exercise maintenance.

本発明の機能水は、メタボリックシンドローム、アディポネクチン、レプチン、TNF−α又は酸化障害に関連した疾患若しくは状態、又は高血圧の治療の目的では、成人一日当たり100ml以上、好ましくは200ml以上経口的に摂取するとよい。予防の目的では、より少ない量で効果がある場合もある。摂取量には特に制限はないが、水素を曝気することにより製造された本発明の機能水を正常血圧者が多飲すると血圧の急激な低下が見られることがあるので、経口摂取の場合の1回量は、500ml未満であることが好ましいであろう。   The functional water of the present invention is orally taken at 100 ml or more, preferably 200 ml or more per day for adults for the purpose of treating metabolic syndrome, adiponectin, leptin, TNF-α or diseases or conditions related to oxidative disorder, or hypertension. Good. For prevention purposes, smaller amounts may be effective. There is no particular restriction on the amount of intake, but if a person with normal blood pressure drinks a large amount of functional water of the present invention produced by aeration of hydrogen, a rapid decrease in blood pressure may be seen. A single dose will preferably be less than 500 ml.

本発明の機能水は、微細な気泡の気体及び水以外に、食品として、化粧品として又は医薬として許容できる種々の添加剤及び成分を含んでもよい。本発明の機能水は、例えば、安定剤、緩衝剤、矯味剤(甘味料、酸味料を含む。)、保存剤、芳香剤、着色剤、粘稠剤、ビタミン類、塩類、果汁、目的とする疾患又は状態の処置のために有効な他の成分を含んでもよい。本発明の機能水を食品、化粧品又は医薬品とする場合、溶液状、乳液状、懸濁状等、種々の液状の形態とすることができ、またそれを固形化若しくは半固形化した、又は封入した、ゲル状、カプセル状とすることができる。   The functional water of the present invention may contain various additives and components that are acceptable as food, cosmetics, or pharmaceuticals, in addition to fine gas bubbles and water. The functional water of the present invention includes, for example, stabilizers, buffers, flavoring agents (including sweeteners and acidulants), preservatives, fragrances, coloring agents, thickeners, vitamins, salts, fruit juices, It may contain other ingredients that are effective for the treatment of the disease or condition. When the functional water of the present invention is used as food, cosmetics or pharmaceuticals, it can be in various liquid forms such as solution, emulsion, suspension, etc., and it is solidified or semi-solidified or encapsulated. It can be in the form of a gel or capsule.

本発明の機能水を充填する容器としては、ペットボトル及びガラスが適している。   As the container filled with the functional water of the present invention, a plastic bottle and glass are suitable.

以下に本発明の内容を詳細に説明する。本発明に用いられる装置類等は本発明を説明するだけのものであり、本発明はこれに限定されるものではない。   The contents of the present invention will be described in detail below. The devices and the like used in the present invention are only for explaining the present invention, and the present invention is not limited to this.

[機能水の製造例1]
セラミック製のタンクに加熱殺菌した20Lの脱イオン水を入れ、ノンオイルのコンプレッサーに接続したナノメーターサイズの孔径を有する有機系のフィルター(旭化成ケミカルズ株式会社製ポリスルフォン限外濾過膜型モジュール、製品名マイクローザペンシル型モジュールSEP-0013、公称分画分子量3,000)を浸漬した。室温下で5〜20時間、2kg/cm2に加圧した空気をモジュールに送り込んだ。このとき、モジュールの排出部を空気が漏出しないように完全に密閉しておいた。
[Functional water production example 1]
20L deionized water pasteurized in a ceramic tank and connected to a non-oil compressor with an organic filter with a nanometer pore size (polysulfone ultrafiltration membrane module manufactured by Asahi Kasei Chemicals Corporation, product name Microza pencil type module SEP-0013, nominal molecular weight cut off 3,000). Air pressurized to 2 kg / cm 2 was sent into the module for 5-20 hours at room temperature. At this time, the discharge part of the module was completely sealed so as not to leak air.

[機能水の製造例2]
セラミック製のタンクに加熱殺菌した20Lの脱イオン水を入れ、ノンオイルのコンプレッサーに接続したナノメーターサイズの孔径を有する無機系のフィルター(株式会社ノリタケカンパニーリミテド製セラミックフィルターモジュール、製品名MEMBRALOX、孔径20nm)を浸漬した。室温下で10〜60分間、10kg/cm2に加圧した空気をモジュールに送り込んだ。このとき、モジュールの排出部を空気が漏出しないように完全に密閉しておいた。
[Functional water production example 2]
Inorganic filter with nanometer pore size (ceramic filter module manufactured by Noritake Co., Ltd., product name MEMBRALOX, pore size 20nm) with 20L of deionized water heat sterilized in a ceramic tank and connected to a non-oil compressor ). Air pressurized to 10 kg / cm 2 was sent into the module for 10-60 minutes at room temperature. At this time, the discharge part of the module was completely sealed so as not to leak air.

[機能水の評価及び保存安定性]
マイクロメーター以下の気泡を含む水はマイナスの電位を有し、水面上に上昇することなく、圧壊現象により水中で消滅する。その際、瞬間的に超高温・超高圧状態になることから、水を構成している水素分子が物理的に解離し、原子状水素になっていると考えらる。原子状水素は還元性を示すことから、最も簡単に測定できる方法は過酸化水素との反応である。原子状水素は、過酸化水素を1:1の等モル反応で消去できる。この消去された過酸化水素量を過酸化水素センサー等の簡易な方法で測定し、機能水の評価方法とした。
[Evaluation of functional water and storage stability]
Water containing bubbles below the micrometer has a negative potential and disappears in the water by a crushing phenomenon without rising on the water surface. At that time, since it is in an ultra-high temperature / ultra-high pressure state instantaneously, it is considered that the hydrogen molecules constituting the water are physically dissociated into atomic hydrogen. Since atomic hydrogen is reducible, the most easily measurable method is reaction with hydrogen peroxide. Atomic hydrogen can eliminate hydrogen peroxide with 1: 1 equimolar reaction. The erased amount of hydrogen peroxide was measured by a simple method such as a hydrogen peroxide sensor, and used as a functional water evaluation method.

製造例1に記した方法で、空気又は水素を曝気することにより機能水を製造した。機能水は冷暗所に0〜3ヶ月保存した。   Functional water was produced by aeration of air or hydrogen by the method described in Production Example 1. Functional water was stored in a cool dark place for 0 to 3 months.

各機能水10mlには、過酸化水素水を過酸化水素濃度が10ppmになるように添加し、密閉し、室温下に3時間静置した後、残存過酸化水素量を過酸化水素センサーで測定した。対照として、機能水の製造に使用した脱イオン水について、同様に残存過酸化水素量を測定した。   To each 10 ml of functional water, hydrogen peroxide solution is added so that the hydrogen peroxide concentration is 10 ppm, sealed, and allowed to stand at room temperature for 3 hours, and then the amount of residual hydrogen peroxide is measured with a hydrogen peroxide sensor. did. As a control, the amount of residual hydrogen peroxide was similarly measured for deionized water used for the production of functional water.

過酸化水素消去能(%)は次式で算出した。
過酸化水素消去能(%)=((AH−RH)/AH)×100
AHは添加過酸化水素濃度、RHは残存過酸化水素濃度である。
The hydrogen peroxide scavenging ability (%) was calculated by the following formula.
Hydrogen peroxide scavenging ability (%) = ((AH-RH) / AH) x 100
AH is the added hydrogen peroxide concentration, and RH is the residual hydrogen peroxide concentration.

結果を下表に示す。   The results are shown in the table below.

Figure 2008156320
Figure 2008156320

対照は過酸化水素消去能をいずれの月において示さなかった為、3ヶ月目のみ記載した。   Since the control did not show hydrogen peroxide scavenging ability in any month, only the third month was listed.

また、過酸化水素消去能について、6サンプルの平均値及び標準偏差値を下表に示す。   In addition, regarding the hydrogen peroxide scavenging ability, the average value and standard deviation value of 6 samples are shown in the following table.

Figure 2008156320
Figure 2008156320

各機能水の過酸化水素消去能は、製造後時間と共に徐々に低下するが、空気を高濃度に包含させた水では2ヶ月間、水素を高濃度に包含させた水では3ヶ月間保存した場合でも約50%の過酸化水素消去能を保持していた。これは製造例で示した方法で、空気や水素を高濃度に水に包含させると、これらの気体が比較的安定な状態で存在していることを示していると考えられる。約2〜3ヶ月間の品質保証が可能で有れば商業的規模で流通させるのも不可能ではない。   The hydrogen peroxide scavenging ability of each functional water gradually decreases with time after production, but it was stored for 2 months with water containing a high concentration of air and for 3 months with water containing a high concentration of hydrogen. Even in this case, it retained about 50% hydrogen peroxide scavenging ability. This is the method shown in the production example, and it is considered that when air or hydrogen is included in water at a high concentration, these gases exist in a relatively stable state. If quality assurance is possible for about 2 to 3 months, it is not impossible to distribute on a commercial scale.

[インビボ試験]
次に、本発明の機能水が生体内で目的の作用を発揮するか否かを確認するために、マウス及びラットでのメタボリックシンドロームに関する実験を実施した。指標として、末梢血のアディポネクチン、レプチン、腫瘍壊滅因子(TNF−α)、過酸化脂質及び血圧を測定した。
[In vivo test]
Next, in order to confirm whether or not the functional water of the present invention exerts the desired action in vivo, experiments on metabolic syndrome in mice and rats were performed. As indicators, peripheral blood adiponectin, leptin, tumor necrosis factor (TNF-α), lipid peroxide and blood pressure were measured.

1. 末梢血のアディポネクチン、レプチン、TNF−αへの影響:
糖尿病マウス(KKAy、♂、7週令、日本クレア社)を温度25±3℃、相対湿度50±10%、明暗サイクル12時間(明期8:00〜20:00)の環境下で飼育し、餌は高脂肪食(日本クレア社)を自由摂取させた。また、上述の、空気を包含させた機能水又は水素を包含させた機能水を飲料水として自由摂取させた。対照として、機能水製造に使用した水道水を用いた。
1. Effects of peripheral blood on adiponectin, leptin, and TNF-α:
Diabetic mice (KKAy, ♂, 7-week-old, CLEA Japan) are raised in an environment with a temperature of 25 ± 3 ° C, relative humidity of 50 ± 10%, and a light / dark cycle of 12 hours (light period 8: 00-20: 00). The diet was a high-fat diet (Claire Japan). In addition, the functional water containing air or the functional water containing hydrogen was freely ingested as drinking water. As a control, tap water used for functional water production was used.

1ヶ月間飼育後、エーテル麻酔下にて眼底静脈から採血し、常法に基づいて血清を得た。血清中のアディポネクチン、レプチン、TNF−αの測定は各々の抗体をBIAcoreセンサーチップに固定化し、BIAcore社の操作マニュアルに基づいて表面プラズモン共鳴法で測定した。各々の結果を下表に示す。   After raising for one month, blood was collected from the fundus vein under ether anesthesia, and serum was obtained based on a conventional method. Adiponectin, leptin, and TNF-α in serum were measured by the surface plasmon resonance method by immobilizing each antibody on a BIAcore sensor chip and based on an operation manual of BIAcore. The results are shown in the table below.

Figure 2008156320
Figure 2008156320

各因子は対照比での割合を示した。+は増加を、−は減少を示す。   Each factor showed the ratio in the control ratio. + Indicates an increase and-indicates a decrease.

2. 酸化障害への影響:
ラット(Wistar/ST、♂、5週令、三協ラボサービス社)を温度25±3℃、相対湿度50±10%、明暗サイクル12時間(明期8:00〜20:00)の環境下で飼育し、餌は普通食(日本クレア社)を自由摂取させた。上述の空気を包含させた機能水を飲料水として自由摂取させた。対照として、機能水製造に使用した水道水を滅菌して用いた。
2. Impact on oxidative damage:
Rats (Wistar / ST, ♂, 5 weeks old, Sankyo Lab Service Co., Ltd.) in an environment with a temperature of 25 ± 3 ° C, relative humidity of 50 ± 10%, and a light / dark cycle of 12 hours (light period 8: 00-20: 00) And was allowed to freely eat a normal diet (Claire Japan). The functional water containing the air was freely ingested as drinking water. As a control, tap water used for functional water production was sterilized.

4週間飼育した後、クメンヒドロパーオキサイド50μl(125μg/kg体重)を腹腔に投与した。3時間後にエーテル麻酔下にて眼底静脈から採血し、常法に基づいて血清を得、血清過酸化物価を測定キット(ワコー純薬社)で測定した。結果を下表に示す。   After rearing for 4 weeks, 50 μl of cumene hydroperoxide (125 μg / kg body weight) was intraperitoneally administered. Three hours later, blood was collected from the fundus vein under ether anesthesia, serum was obtained based on a conventional method, and the serum peroxide value was measured with a measurement kit (Wako Pure Chemical Industries). The results are shown in the table below.

Figure 2008156320
Figure 2008156320

クメンヒドロパーオキサイドを投与した後の血清過酸化脂質濃度は、滅菌水道水で飼育した対照群では約40%上昇していたのに対し、機能水を摂取させることにより、上昇率は9%程度に抑制された。   The serum lipid peroxide level after administration of cumene hydroperoxide was about 40% higher in the control group fed with sterile tap water, but the rate of increase was about 9% by ingesting functional water. Was suppressed.

3. 血圧に及ぼす影響:
高血圧自然発症ラット(SHR/izm、♂、8週令、三協ラボサービス社)を温度25±3℃、相対湿度50±10%、明暗サイクル12時間(明期8:00〜20:00)の環境下で飼育し、餌はCE-2固形飼料(日本クレア社)を自由摂取させた。また、上述の空気を包含させた機能水又は水素を包含させた機能水をそれぞれ飲料水として自由摂取させた。対照として、機能水製造に使用した水道水を滅菌して使用した。この条件下で4ヶ月間飼育した。血圧をマウス・ラット用非観血式血圧計(MODEL MK-2000、室町機械社)で測定した。
3. Effects on blood pressure:
Spontaneously hypertensive rats (SHR / izm, ♂, 8 weeks old, Sankyo Lab Service Co., Ltd.), temperature 25 ± 3 ° C, relative humidity 50 ± 10%, light / dark cycle 12 hours (light period 8: 00-20: 00) And was fed freely with CE-2 solid feed (Claire Japan). Moreover, the functional water which included the above-mentioned air or the functional water which included hydrogen was each ingested freely as drinking water. As a control, tap water used for functional water production was sterilized. The animals were raised for 4 months under these conditions. Blood pressure was measured with a non-invasive blood pressure monitor for mice and rats (MODEL MK-2000, Muromachi Kikai Co., Ltd.).

高血圧自然発症ラットの結果を表4-1及び表4-2に示す。   The results of spontaneously hypertensive rats are shown in Table 4-1 and Table 4-2.

Figure 2008156320
Figure 2008156320

Figure 2008156320
Figure 2008156320

各動物個体の血圧は6回の測定の平均値を、( )内の数字は標準偏差値を表す。   The blood pressure of each animal represents the average value of 6 measurements, and the numbers in () represent standard deviation values.

拡張期血圧は収縮期と平均血圧の測定値からマウス・ラット用非観血式血圧計(MODEL MK-2000、室町機械社)に内蔵されているソフトウエアーで算出された値である。   The diastolic blood pressure is a value calculated by the software built in the non-invasive blood pressure monitor for mice and rats (MODEL MK-2000, Muromachi Kikai Co., Ltd.) from the measured values of the systolic phase and the average blood pressure.

表4-1及び表4-2に示したように、本発明の機能水は、いずれも血圧を低下させる作用を有していた。その作用は空気の場合よりも、水素を包含させた方が高かった。   As shown in Table 4-1 and Table 4-2, the functional water of the present invention had an action of lowering blood pressure. The effect was higher when hydrogen was included than with air.

5. ヒトボランティアの血圧に及ぼす影響:
高血圧症の境界領域4名と正常血圧1名のヒト男性ボランティアに朝、昼、晩の任意の時間に空気を包含させた機能水各200ml飲用させ、30分間後の収縮期と拡張期の血圧を測定した。血圧は家庭用血圧計(オムロン社)を用い、操作マニュアルに基づき同一施設内にて同一条件下で測定した。この間、高血圧の治療薬(血圧降下剤)を使用していないことを確認している。結果を下表に示す。
5. Effects on blood pressure of human volunteers:
A human male volunteer with 4 hypertension border areas and 1 normal blood pressure had 200 ml of functional water inclusive of air at any time of morning, noon, and evening, and blood pressure in the systolic and diastolic phases 30 minutes later Was measured. Blood pressure was measured using the home blood pressure monitor (OMRON) under the same conditions in the same facility based on the operation manual. During this period, it was confirmed that no antihypertensive drugs (antihypertensive agents) were used. The results are shown in the table below.

Figure 2008156320
Figure 2008156320

5*は正常血圧のボランティアである。   5 * are normotensive volunteers.

ヒトでも動物実験の場合と同様に、本発明の機能水は拡張期、収縮期血圧を10〜18%も低下させた。   In humans, as in animal experiments, the functional water of the present invention reduced diastolic and systolic blood pressure by 10 to 18%.

Claims (9)

空気、水素、酸素及び窒素からなる群より選択される気体の一種以上を曝気することにより生じた微細な気泡を含み、過酸化水素除去能を有する機能水。 Functional water containing fine bubbles generated by aeration of one or more gases selected from the group consisting of air, hydrogen, oxygen and nitrogen, and having hydrogen peroxide removal ability. 空気、水素、酸素及び窒素からなる群より選択される気体の一種以上を、精密濾過膜、限外濾過膜、又はガス分離膜を介して曝気することにより生じた微細な気泡を含む機能水。 Functional water containing fine bubbles generated by aeration of one or more gases selected from the group consisting of air, hydrogen, oxygen, and nitrogen through a microfiltration membrane, an ultrafiltration membrane, or a gas separation membrane. 過酸化水素除去能を有する、請求項2に記載の機能水。 The functional water according to claim 2, which has hydrogen peroxide removing ability. メタボリックシンドローム、アディポネクチン、レプチン、TNF−α又は酸化障害に関連した疾患若しくは状態、又は高血圧の処置のための、請求項1〜3のいずれか1項に記載の機能水。 Functional water according to any one of claims 1 to 3, for the treatment of metabolic syndrome, adiponectin, leptin, TNF-α or diseases or conditions associated with oxidative disorders, or hypertension. 空気、水素、酸素及び窒素からなる群から選択される気体の一種以上を曝気することにより生じた微細な気泡を含む、抗酸化性機能水。 Antioxidant functional water containing fine bubbles generated by aeration of one or more gases selected from the group consisting of air, hydrogen, oxygen and nitrogen. 請求項5に記載の機能水を含む、食品組成物、化粧用組成物又は医薬組成物。 A food composition, cosmetic composition or pharmaceutical composition comprising the functional water according to claim 5. 請求項5に記載の機能水を含む、メタボリックシンドローム、アディポネクチン、レプチン、TNF−α又は酸化障害に関連した疾患若しくは状態、又は高血圧の処置のための医薬組成物。 A pharmaceutical composition for the treatment of metabolic syndrome, adiponectin, leptin, TNF-α or a disease or condition associated with oxidative disorder, or hypertension, comprising the functional water according to claim 5. 空気が理論溶存値の少なくとも50倍含まれる、請求項1〜3のいずれか1項に記載の機能水。 The functional water according to any one of claims 1 to 3, wherein air is contained at least 50 times the theoretical dissolved value. 水素が理論溶存値の少なくとも10倍含まれる、請求項1〜3のいずれか1項に記載の機能水。 The functional water according to any one of claims 1 to 3, wherein hydrogen is contained at least 10 times the theoretical dissolved value.
JP2006350037A 2006-12-26 2006-12-26 Antioxidative functional water Pending JP2008156320A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006350037A JP2008156320A (en) 2006-12-26 2006-12-26 Antioxidative functional water

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006350037A JP2008156320A (en) 2006-12-26 2006-12-26 Antioxidative functional water

Publications (1)

Publication Number Publication Date
JP2008156320A true JP2008156320A (en) 2008-07-10

Family

ID=39657652

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006350037A Pending JP2008156320A (en) 2006-12-26 2006-12-26 Antioxidative functional water

Country Status (1)

Country Link
JP (1) JP2008156320A (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009054481A1 (en) * 2007-10-25 2009-04-30 Suntory Holdings Limited Method of producing carbonated drink
JP2010059065A (en) * 2008-09-02 2010-03-18 Asuka Yume:Kk Slimming cosmetic
JP2010195719A (en) * 2009-02-25 2010-09-09 I'rom Pharmaceutical Co Ltd Liquid composition for preventing or improving sensorineural hearing impairment
JP2012525396A (en) * 2009-04-27 2012-10-22 レバレジオ コーポレイション Compositions and methods for treating insulin resistance and diabetes mellitus
JP2014139225A (en) * 2014-03-28 2014-07-31 Opt Creation:Kk Nanobubble hydrogen water containing fucoidan
US9011922B2 (en) 2009-04-27 2015-04-21 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
WO2015099201A1 (en) * 2013-12-27 2015-07-02 アクア・ゼスト株式会社 Nanobubble-containing composition and use thereof
US9402803B2 (en) 2006-10-25 2016-08-02 Revalesio Corporation Methods of wound care and treatment
US9492404B2 (en) 2010-08-12 2016-11-15 Revalesio Corporation Compositions and methods for treatment of taupathy
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
JP2017038528A (en) * 2015-08-17 2017-02-23 株式会社テックコーポレーション Cleaning method and cleaning solution
JP2017143752A (en) * 2016-02-15 2017-08-24 Hack Japan ホールディングス株式会社 supplement
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
JP2018184354A (en) * 2017-04-25 2018-11-22 国立大学法人岐阜大学 Liquid for preventing or improving diabetes
WO2021075043A1 (en) * 2019-10-18 2021-04-22 国立大学法人 東京大学 Ultrafine bubble-containing solution, beverage containing this, and drug
CN114469758A (en) * 2022-01-25 2022-05-13 中国科学院上海应用物理研究所 Small-particle-size nano bubble water and preparation method and application thereof

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005040765A (en) * 2003-07-25 2005-02-17 Wataru Murota Anti-oxidizing water and anti-oxidizing drink
JP2005126384A (en) * 2003-10-24 2005-05-19 Mizu Kk Pharmacologically functional water and its use
JP2005246294A (en) * 2004-03-05 2005-09-15 National Institute Of Advanced Industrial & Technology Oxygen-nanobubble water and production method therefor
JP2005296794A (en) * 2004-04-12 2005-10-27 Ted:Kk Hydrogen reduction water production method
JP2006167683A (en) * 2004-12-20 2006-06-29 Noritz Corp Apparatus for producing hydrogen water
JP2006320675A (en) * 2005-05-19 2006-11-30 Hitoshi Takahashi Application of micro bubble by carbon dioxide
JP2008006365A (en) * 2006-06-28 2008-01-17 Kawakuriin:Kk Continuous producing method of hydrogen water, its producing apparatus, bathing apparatus using hydrogen water, and bathroom device
JP2008036521A (en) * 2006-08-04 2008-02-21 Spring:Kk Method for activating and stabilizing dissolved hydrogen in water
JP2008043906A (en) * 2006-08-19 2008-02-28 Nanoplanet Kenkyusho:Kk Functional microbubble and functional microbubble water
WO2008026785A1 (en) * 2006-08-31 2008-03-06 Shigeo Ohta Lipid metabolism improving agent containing hydrogen molecule
WO2008072370A1 (en) * 2006-12-12 2008-06-19 National University Corporation Tokyo Medical And Dental University Preparation for tissue repair or regeneration

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005040765A (en) * 2003-07-25 2005-02-17 Wataru Murota Anti-oxidizing water and anti-oxidizing drink
JP2005126384A (en) * 2003-10-24 2005-05-19 Mizu Kk Pharmacologically functional water and its use
JP2005246294A (en) * 2004-03-05 2005-09-15 National Institute Of Advanced Industrial & Technology Oxygen-nanobubble water and production method therefor
JP2005296794A (en) * 2004-04-12 2005-10-27 Ted:Kk Hydrogen reduction water production method
JP2006167683A (en) * 2004-12-20 2006-06-29 Noritz Corp Apparatus for producing hydrogen water
JP2006320675A (en) * 2005-05-19 2006-11-30 Hitoshi Takahashi Application of micro bubble by carbon dioxide
JP2008006365A (en) * 2006-06-28 2008-01-17 Kawakuriin:Kk Continuous producing method of hydrogen water, its producing apparatus, bathing apparatus using hydrogen water, and bathroom device
JP2008036521A (en) * 2006-08-04 2008-02-21 Spring:Kk Method for activating and stabilizing dissolved hydrogen in water
JP2008043906A (en) * 2006-08-19 2008-02-28 Nanoplanet Kenkyusho:Kk Functional microbubble and functional microbubble water
WO2008026785A1 (en) * 2006-08-31 2008-03-06 Shigeo Ohta Lipid metabolism improving agent containing hydrogen molecule
WO2008072370A1 (en) * 2006-12-12 2008-06-19 National University Corporation Tokyo Medical And Dental University Preparation for tissue repair or regeneration

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6012044122; 宮崎県工業技術センター・宮崎県食品開発センター研究報告 Vol.50, 2005, pp.9-11 *
JPN6012044123; 膜 Vol.18 , No.4, 1993, pp.196-206 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9402803B2 (en) 2006-10-25 2016-08-02 Revalesio Corporation Methods of wound care and treatment
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
WO2009054481A1 (en) * 2007-10-25 2009-04-30 Suntory Holdings Limited Method of producing carbonated drink
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
JP2010059065A (en) * 2008-09-02 2010-03-18 Asuka Yume:Kk Slimming cosmetic
JP2010195719A (en) * 2009-02-25 2010-09-09 I'rom Pharmaceutical Co Ltd Liquid composition for preventing or improving sensorineural hearing impairment
US9011922B2 (en) 2009-04-27 2015-04-21 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
US9272000B2 (en) 2009-04-27 2016-03-01 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
JP2012525396A (en) * 2009-04-27 2012-10-22 レバレジオ コーポレイション Compositions and methods for treating insulin resistance and diabetes mellitus
US9492404B2 (en) 2010-08-12 2016-11-15 Revalesio Corporation Compositions and methods for treatment of taupathy
JP2016063804A (en) * 2013-12-27 2016-04-28 亀井 一郎 Mitochondrial activation composition
WO2015099201A1 (en) * 2013-12-27 2015-07-02 アクア・ゼスト株式会社 Nanobubble-containing composition and use thereof
JP2014139225A (en) * 2014-03-28 2014-07-31 Opt Creation:Kk Nanobubble hydrogen water containing fucoidan
JP2017038528A (en) * 2015-08-17 2017-02-23 株式会社テックコーポレーション Cleaning method and cleaning solution
JP2017143752A (en) * 2016-02-15 2017-08-24 Hack Japan ホールディングス株式会社 supplement
JP2018184354A (en) * 2017-04-25 2018-11-22 国立大学法人岐阜大学 Liquid for preventing or improving diabetes
JP7149053B2 (en) 2017-04-25 2022-10-06 株式会社田中金属製作所 Liquids for prevention or improvement of diabetes
WO2021075043A1 (en) * 2019-10-18 2021-04-22 国立大学法人 東京大学 Ultrafine bubble-containing solution, beverage containing this, and drug
CN114469758A (en) * 2022-01-25 2022-05-13 中国科学院上海应用物理研究所 Small-particle-size nano bubble water and preparation method and application thereof
CN114469758B (en) * 2022-01-25 2024-02-20 中国科学院上海应用物理研究所 Small-particle-size nano bubble water and preparation method and application thereof

Similar Documents

Publication Publication Date Title
JP2008156320A (en) Antioxidative functional water
US5597585A (en) Vitamin/mineral composition
DK2218342T3 (en) New nutraceutical compositions and their use
JP4739161B2 (en) Endurance improver
WO2008026785A1 (en) Lipid metabolism improving agent containing hydrogen molecule
KR20060134181A (en) Hydroxymethylbutyrate compositions and uses thereof
JP2015127301A (en) Visceral fat reducing agent and fat synthesis inhibiting agent comprising hydrogen nanobubble water
KR20140103289A (en) Medical food for the dietary management of depression and anxiety and methods thereof
RU2343724C1 (en) Method of manufacturing biologically active products from brown algae
CN106491582A (en) Anti- liquor-saturated preparation containing dihydromyricetin and application thereof
JP2008239598A (en) Liquid composition
JP2007320900A (en) Agent for inhibiting visceral fat accumulation and agent for promoting increase in and/or inhibiting decrease in blood adiponectin concentration
WO2007009314A1 (en) A device for generating oxygen-enriched water
Barešic et al. Survival after severe acute chromic acid poisoning complicated with renal and liver failure
KR100756550B1 (en) Composition containing pterocarpus santalinus extract for the prevention and treatment of hyperlipidemia and fatty liver
JP6112767B2 (en) Composition for lowering uric acid level in blood
JP4891522B2 (en) Serum GOT, GPT improving agent
CN111989097A (en) Composition for preventing or treating acute radiation syndrome
JP2020186205A (en) Vasodilator
JP2007314439A (en) Physical strength enhancer
JP2004161730A (en) New blood pressure elevation suppressing substance
EP1864671A1 (en) The use of hydrochloric acid for the manufacture of a medicament for the treatment of hypertension
JPWO2009054360A1 (en) Visceral fat specific reducing agent
WO2008089776A1 (en) Formulation of and method for producing an infusion rehydration solution
JP7149053B2 (en) Liquids for prevention or improvement of diabetes

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20071113

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20071113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091228

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120822

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121211